Going past the data for temozolomide
| Autor: | J. Lee Villano, Nathalie Letarte, Linda R. Bressler |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
Oncology
Cancer Research medicine.medical_specialty Standard of care medicine.medical_treatment Brain tumor Newly diagnosed Toxicology Internal medicine Temozolomide medicine Adjuvant therapy Humans Pharmacology (medical) Antineoplastic Agents Alkylating Pharmacology Brain Neoplasms business.industry medicine.disease humanities Dacarbazine Clinical Practice Treatment Outcome Chemotherapy Adjuvant Glioblastoma business Adjuvant medicine.drug |
| Zdroj: | Cancer Chemotherapy and Pharmacology. 69:1113-1115 |
| ISSN: | 1432-0843 0344-5704 |
| DOI: | 10.1007/s00280-011-1796-4 |
| Popis: | The benefit of six cycles of adjuvant temozolomide was documented in a randomized phase III (EORTC-NCIC CE.3) trial, and this therapy, following combined temozolomide and radiation, is the standard of care for patients with newly diagnosed glioblastoma. We comment on the differences in the length of adjuvant therapy in both clinical practice and national studies (e.g. RTOG 0825), usually doubling the length in the EORTC/NCIC study, and relate to historic adjuvant trials for solid tumors. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink